- Home
- KFS vs MRSN Comparison
KFS vs MRSN Comparison
Compare KFS & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFS
- MRSN
- Stock Information
- Founded
- KFS 1989
- MRSN 2001
- Country
- KFS United States
- MRSN United States
- Employees
- KFS N/A
- MRSN N/A
- Industry
- KFS Property-Casualty Insurers
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- KFS Finance
- MRSN Health Care
- Exchange
- KFS Nasdaq
- MRSN Nasdaq
- Market Cap
- KFS 234.2M
- MRSN 252.0M
- IPO Year
- KFS 1996
- MRSN 2017
- Fundamental
- Price
- KFS $8.16
- MRSN $0.62
- Analyst Decision
- KFS
- MRSN Buy
- Analyst Count
- KFS 0
- MRSN 6
- Target Price
- KFS N/A
- MRSN $6.00
- AVG Volume (30 Days)
- KFS 59.7K
- MRSN 7.3M
- Earning Date
- KFS 03-04-2025
- MRSN 02-26-2025
- Dividend Yield
- KFS N/A
- MRSN N/A
- EPS Growth
- KFS N/A
- MRSN N/A
- EPS
- KFS N/A
- MRSN N/A
- Revenue
- KFS $108,627,000.00
- MRSN $34,837,000.00
- Revenue This Year
- KFS N/A
- MRSN N/A
- Revenue Next Year
- KFS N/A
- MRSN N/A
- P/E Ratio
- KFS N/A
- MRSN N/A
- Revenue Growth
- KFS 2.02
- MRSN N/A
- 52 Week Low
- KFS $7.60
- MRSN $0.56
- 52 Week High
- KFS $9.58
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- KFS 43.16
- MRSN 20.37
- Support Level
- KFS $7.74
- MRSN $0.56
- Resistance Level
- KFS $8.38
- MRSN $1.45
- Average True Range (ATR)
- KFS 0.18
- MRSN 0.14
- MACD
- KFS 0.02
- MRSN -0.06
- Stochastic Oscillator
- KFS 51.22
- MRSN 6.49
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.